Equity Research firms currently have a positive stance on shares of Proteon Therapeutics Inc (NASDAQ:PRTO). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $20.67 on a short term basis.
At the time of writing, the stock was trading at $8.75. This represents a change from the opening price of 0.46%. In terms of performance, year to date, the stock is -43.26%. The monthly stock performance comes in at -4.86%. For the quarter, shares are performing at 8.11%. Weekly performance analysis shows the equity at -3.72%.
In taking a look at technical levels, shares are trading -2.87% away from the 50 day simple moving average and 4.60% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -50.73% away from it’s 52- week high and 78.57% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Proteon Therapeutics Inc’s RSI stands at 48.75. In looking at volatility levels, the shares saw weekly volatility of 4.27% and 7.56% over the past month.